

HHS Public Access

Circ Genom Precis Med. Author manuscript; available in PMC 2019 May 01.

Published in final edited form as:

Author manuscript

Circ Genom Precis Med. 2018 May ; 11(5): e002037. doi:10.1161/CIRCGEN.117.002037.

Common and Rare Coding Genetic Variation Underlying the Electrocardiographic PR Interval

A full list of authors and affiliations appears at the end of the article.

Abstract

Background—Electrical conduction from the cardiac sinoatrial node to the ventricles is critical for normal heart function. Genome-wide association studies (GWAS) have identified more than a dozen common genetic loci that are associated with PR interval. However, it is unclear whether rare and low-frequency variants also contribute to PR interval heritability.

Methods and Results—We performed large-scale meta-analysis of the PR interval that included 83,367 participants of European ancestry and 9,436 of African ancestry. The Illumina HumanExome BeadChip examined both common and rare variants. We identified 31 genetic loci that were significantly associated with PR interval after Bonferroni correction ($P<1.2\times10^{-6}$), including 11 novel loci that have not been reported previously. Many of these loci are involved in heart morphogenesis. In gene-based analysis, we found that multiple rare variants at MYH6 ($P=5.9\times10^{-11}$) and SCN5A ($P=1.1\times10^{-7}$) were associated with PR interval. SCN5A locus also was implicated in the common variant analysis, whereas MYH6 was a novel locus.

Conclusion—We identified common variants at 11 novel loci and rare variants within two gene regions that were significantly associated with PR interval. Our findings provide novel insights to the current understanding of atrioventricular conduction, which is critical for cardiac activity and an important determinant of health.

Keywords

ECG; genetics; association studies; epidemiology; genetics; PR interval; exome chip

Journal Subject Terms

Electrophysiology; Epidemiology; Genetic Association Studies

Introduction

Electrical conduction from the cardiac sinoatrial node to the ventricles is critical for normal heart function. Abnormalities of atrioventricular conduction can cause significant morbidity, and have been associated with atrial fibrillation (AF),^{1,2} need for pacemaker implantation,²

Correspondence: Honghuang Lin, PhD, Section of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, 72 East Concord Street, B-616, Boston, MA 02118, Tel: 617-638-7649, Fax: 617-638-8086, hhlin@bu.edu; Steven A. Lubitz, MD, MPH, Cardiac Arrhythmia Service & Cardiovascular Research Center, Massachusetts General Hospital, 55 Fruit Street, GRB 109, Boston, MA 02114, Tel: 617-643-7339, Fax: 617-726-3852, slubitz@mgh.harvard.edu. Contributed equally

cardiac malformations, and sudden death.^{3,4} Conduction from the sinus node through the atria, atrioventricular node, and His-Purkinje fibers is readily evaluated from surface electrocardiogram (ECG), by measurement of the duration of PR interval. Despite the critical role that the cardiac conduction system plays in cardiac physiology and disease, the formation and regulation of the conduction system remains incompletely understood.

Recent data indicate that cardiac conduction measurements are heritable^{5–7} and have a genetic basis.^{8–11} To date, genetic studies of PR interval have been relatively modest-sized largely European-ancestry samples, and have implicated cardiac expressed ion channels, cardiac developmental transcription factors, signaling molecules, as well as novel pathways not previously known to be involved in cardiac conduction processes. Nevertheless, existing studies have focused on the role of common and predominantly noncoding genetic variants, which account for only a modest proportion of trait heritability.⁶

To better understand the biological and potential clinical implications of genetic variation underlying cardiac conduction, there is a need to examine both common and rare variation underlying atrioventricular conduction in large, well-powered, multiethnic studies. Moreover, assessment of genetic variation that alters protein coding has the potential to more directly implicate genes involved in processes critical to cardiac conduction. We therefore sought to examine PR interval duration in relation to predominantly coding genetic variants, in large, multi-ethnic analyses using the exome chip.

Methods

The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results, subject to Data Use/Sharing Agreements adopted by individual participating cohorts. The summary results from the current manuscript are available at the Broad Cardiovascular Disease Knowledge Portal (www.broadcvdi.org).

Study participants

The current project included participants of European ancestry (EA) from 22 studies: Age, Gene/Environment Susceptibility Study (AGES); Atherosclerosis Risk in Communities study (ARIC); British Genetics of Hypertension (BRIGHT); Massachusetts General Hospital Cardiology and Metabolic Patient cohort (CAMP); Cardiovascular Health Study (CHS); Erasmus Rucphen Family Study (ERF); Framingham Heart Study (FHS); Genes for Cerebral Hemorrhage on Anticoagulation (GOCHA); Genetic Regulation of Arterial Pressure In Humans in the Community (GRAPHIC); INTER99; Cooperative Health Research in the Region Augsburg (KORA); CROATIA-Korcula (KORCULA); LifeLines Cohort Study (LifeLines); Multi-Ethnic Study of Atherosclerosis (MESA); The Netherlands Epidemiology of Obesity (NEO); Rotterdam Study (RS); Generation Scotland: Scottish Family Health Study (GS:SFHS); Study of Health in Pomerania (SHIP); TwinsUK; Utrecht Health Project (UHP); Women's Health Initiative (WHI); and Young Finns Study (YFS).

In addition, we included participants of African ancestry (AA) from five studies. These studies included ARIC, CHS, Jackson Heart Study (JHS), MESA and WHI.

Institutional Review Boards or Ethics Committees approved study procedures at each contributing site. All participants provided written informed consent to participate in genetic research.

Measurement of PR interval

PR interval duration, in milliseconds, was measured from the onset of the P wave to the onset of the QRS interval for each cohort. The following exclusions were applied: extreme PR values (80 ms or 320 ms); second or third degree heart block; atrial fibrillation on baseline ECG; history of myocardial infarction, heart failure, or Wolff–Parkinson–White syndrome; pacemaker placement; use of class I or III blocking medications (ATC code prefix C01B); digoxin use (ATC code C01AA05) or pregnancy.

Genotyping

Genotyping was performed independently in each study using the Illumina Human Exome BeadChip (v1.0, 1.1, or 1.2). Data were called and cleaned according to CHARGE ExomeChip best practices.¹² Detailed information for each study regarding genotyping platforms, variant calling, and quality control metrics is shown in Supplementary Table 1. All studies used the same set of reference alleles to recode variants to ensure consistency.

Statistical analyses

Prior to association analysis, PR interval was first adjusted for covariates by taking residuals from a linear regression of PR on age, sex, height, body mass index, and RR interval. Each cohort additionally adjusted as necessary for cohort-specific variables, such as clinic sites, family structure, and population structure. To reduce sensitivity to extreme PR values, the residuals were inverse-normal transformed and used as the outcome for association testing.

Because single-marker based analyses typically have low power to identify associations between rare variants and traits, we separated the analysis for common and rare variants based on minor allele frequency (MAF). Common variants were defined as those with MAF 1%, and the remaining variants were defined as rare variants (MAF<1%). For each of the common variants, we evaluated its association with the transformed PR interval, and accounted for multiple testing by Bonferroni correction ($P < 0.05/42075 = 1.2 \times 10^{-6}$). For the rare variants, we restricted analyses to nonsynonymous or splicing variants with MAF <1%, because such variants are more likely to be functional than synonymous or more common variants. As we expect some rare variants may act in the same or opposite directions even in the same gene region,¹³ we used a modified version of the Sequence Kernel Association Test (SKAT),¹⁴ which avoids problems of signals cancelling out each other in burden test results. Many gene regions had few or no rare nonsynonymous or splicing variants. Monomorphic variants from each study also were reported in the cohort level results as they were used for the cumulative MAF computations in gene-based tests. Gene regions with a cumulative MAF of rare variants <1% were excluded, resulting in 5,761 gene regions that were tested (see results below). Therefore, Bonferroni-corrected significance threshold for our genebased tests was $P < 0.05/5,761 = 8.7 \times 10^{-6}$. In secondary analyses, we limited the analysis to damaging variants, defined as nonsense variants or variants predicted to be damaging by PolyPhen-2¹⁵ or SIFT.¹⁶

Analyses were performed using the "prepScores" function of the "seqMeta" R package. Family-based studies implemented the "kins" option in "prepScores" to specify kinship matrices. Each study provided single variant z-statistics from score tests, as well as genotype covariance matrices, which were then combined by fixed effects meta-analysis. The heterogeneity across studies was assessed by the Cochran's Q, which is a non-parametric statistical test defined as the weighted sum of squared differences between individual study effects and the pooled effect. We performed both race stratified and race combined metaanalyses, and the race combined results were used for the remaining sections unless stated otherwise.

Comparison with genetic loci associated with AF and P-wave indices (PWI)

We also compared genetic loci associated with PR interval with those associated with AF and PWI to see if there are any shared genetic mechanisms. "AF loci" were identified by a recent exome chip analysis that included 22,806 AF cases and 132,612 referents.¹⁷ "PWI loci" were identified from a meta-analysis of P-wave duration and P-wave terminal force that included 44,456 participants.¹⁸ In addition, for each of the top variants associated with PR, we also examined its association with AF and PWI.

Examine potential function of PR-related variants for gene expression, regulation and biological pathways

Pathway analysis was performed by MAGENTA¹⁹ with default settings. The summary result for the common variants was used as the input, and significant pathways were defined as those with a false discovery rate $(FDR)^{20} < 0.05$. The implication of genetic variants on cardiac gene expression (eOTL analysis) was performed by querying the GTEx database.²¹ At each PR-related locus, we identified the top variant and its neighboring variants that were within 500kb and in linkage disequilibrium with the top variant ($r^2 = 0.5$). Four heart and vascular tissues were queried, including artery aorta, artery coronary, atrial appendage and heart left ventricle. Significant eQTLs were defined as those with FDR<0.05. Regulatory regions were downloaded from the ENCODE Project²² and the NIH Roadmap Epigenomics Program.²³ Four tracks were created: 1) included all 98 cell types from Roadmap epigenomics H3K27ac sites; 2) included only four heart tissues (aorta, right atrium, left ventricle, right ventricle) from Roadmap epigenomics H3K27ac sites; 3) included all 125 cell lines from ENCODE DNaseHS sites; 4) included only three heart-derived cell lines (cardiac fibroblasts, atrial fibroblasts, cardiac myocytes). The enrichment of PR-related loci in regulatory regions was examined by the "VSE" R package.²⁴ For comparison, we randomly created 1,000 variant sets with MAF values and LD structures similar to those seen for PR-related loci.

Results

The current analyses included a total of 92,803 individuals from 27 cohorts, with 83,367 individuals from 22 studies of European ancestry and 9,436 individuals from 5 studies of African ancestry. Clinical characteristics of the study participants are in Table 1.

Identification of 31 loci associated with PR interval

A total of 42,075 common variants were analyzed (MAF 1%). As shown in Figure 1 and Table 2, 31 loci were significantly associated with PR interval after Bonferroni correction ($P < 1.2 \times 10^{-6}$), including 22 loci that reached the conventional genome-wide significance threshold ($P < 5 \times 10^{-8}$). The results of the random effects meta-analysis were similar to those of the fixed effects analysis (Supplementary Table 2). The most significant locus was tagged by rs6795970 (P= 4.0×10⁻²⁴⁰), a missense variant in *SCN10A*, which encodes a sodium channel that has been associated previously with the PR interval (r^2 =0.97 with the top SNP rs6599250 reported previously).⁸ Highly associated variants clustered in the linker region between the second and third domains of *SCN10A* (Figure 2). The top variants at 12 loci are missense variants. In addition, the top variants at 4 loci (including 3 novel loci) are low-frequency variants (1% < MAF < 5%), illustrating the power of exome chip analyses to identify low-frequency coding associations. Detailed information of the nearest gene to each genome wide significant locus is given in Supplementary Table 3.

We then examined the associations between these top PR variants with AF and electrocardiographic PWI. Eight out of 31 PR loci identified in our analysis were associated with AF after Bonferroni correction ($P < 0.05/31 = 1.6 \times 10^{-3}$), consistent with some shared mechanisms between the regulation of PR interval and AF. Variants in *SCN10A* most significantly associated with PR interval were also significantly associated with AF (Supplementary Table 4). Among PR-related SNPs, rs60632610 at the *SYNPO2L* locus was most significantly associated with AF (Odds ratio: 1.90 (0.87-0.93), $P=1.5\times10^{-10}$). Supplementary Figure 1 shows the overlap among loci associated with PR interval, AF, and PWI.

We also performed a sensitivity analysis that separated samples of European and African ancestry. As shown in Supplementary Table 5 and Supplementary Figure 2, all of the 31 loci except rs17391905 at the 1p32.3 locus ($P = 2.6 \times 10^{-6}$) were also significant in the analysis of European-only samples. Supplementary Table 6 and Supplementary Figure 3 show the result for the analysis of African ancestry-only samples. Three loci were significant: *SCN5A* (rs3922844), *SCN10A* (rs6795970), and *TBX5* (rs883079) after Bonferroni correction; $P < 1.3 \times 10^{-6}$. All three loci were also significant in the analysis of European-only samples. The result from each individual study is shown in Supplementary Table 7.

Rare variations in MYH6 and SCN5A are associated with PR interval

We next examined the association between PR interval and rare variants (MAF<1%) in gene regions. Variation in two gene regions, MYH6 ($P = 5.9 \times 10^{-11}$) and SCN5A ($P = 1.1 \times 10^{-7}$), was associated with PR interval (Table 3). Supplementary Tables 8 and 9 show the association of each rare variant within MYH6 and SCN5A with PR interval, respectively. MYH6 encodes a cardiac myosin heavy chain subunit, and SCN5A encodes the major cardiac sodium channel and was previously found to be associated with PR interval.⁸ MYH6 was also recently found to associate with PWI.¹⁸ We also performed an ancestry-stratified analysis in the same way as the combined analysis. The same two gene regions were significant using data from European samples alone ($P = 4.1 \times 10^{-12}$ and 8.3×10^{-7} for MYH6 and SCN5A, respectively). These two genes did not reach the significance cutoff in African

samples (P= 0.03 and 0.01 for *MYH6* and *SCN5A*, respectively). Two other genes, *HEATR2* (P= 2.2×10⁻⁻⁶) and *THRAP3* (P= 4.2×10⁻⁶), were significantly associated in African samples alone. However, in the combined analysis, these two genes were not significant (P=0.02 and 0.06 for *HEATR2* and *THRAP3*, respectively), probably due to a low cumulative allele frequency.

In our secondary analysis of pooled samples, we analyzed only damaging variants, defined as nonsense mutations or alternations predicted to be damaging by PolyPhen-2¹⁵ or SIFT.¹⁶ Three genes reached the signifiance cutoff ($P<0.05/2030=2.5\times10^{-5}$), including *GORASP1* ($P=1.1\times10^{-5}$), *NEBL* ($P=1.9\times10^{-5}$), and *SCN5A* ($P=2.2\times10^{-5}$) (Supplementary Table 10).

Expression quantitative trait loci (eQTL) analysis

We also performed eQTL analysis to determine if any of the novel PR-related variants were associated with cardiac gene expression using data from GTEx.²¹ Eight loci were associated with expression of at least one gene in the atrial appendage, left ventricle, coronary artery, or aorta, suggesting the importance of these loci in the regulation of gene expression in heart or vascular tissues (Supplementary Table 11).

Enrichment of PR-related variants in regulatory regions

We examined involvement of PR-related variants in regulatory function. As shown in Supplementary Figure 4, PR-related variants were significantly enriched in regulatory regions in both primary heart tissues ($P_{adj}=3.7\times10^{-9}$) and heart-derived cell lines ($P_{adj}=0.002$), but not in all tissues ($P_{adj}>0.05$). The observed enrichment suggested involvement of these loci in tissue-specific regulatory functions. In addition, the variants also tended to locate within evolutionarily conserved regions ($P_{adj}=2.8\times10^{-5}$ for primates and 6.4×10^{-5} for mammals).

Enrichment of PR-related variants in biological pathways

We examined the enrichment of PR-related variants in biological pathways by MAGENTA. ¹⁹ Supplementary Table 12 shows the top pathways identified. The most significant pathway was heart morphogenesis ($P=3.6\times10^{-5}$, FDR=0.049), suggesting that many PR-related genes might be involved in cardiac development. The pathway was only the significant pathway after correction for multiple testing (FDR<0.05).

Discussion

We conducted a large-scale analysis of the genetic determinants of atrioventricular conduction in 92 803 individuals by studying the electrocardiographic PR interval. In total, we observed 31 genetic loci that were associated with atrioventricular conduction, 11 of which are novel. In aggregate, the results implicate loci containing genes encoding ion channels in the heart, sarcomeric proteins, cardiac transcription factors, and other proteins with unknown cardiac function. Our findings provide new insights to the current understanding of atrioventricular conduction, which is critical for cardiac function.

Our observations support and extend prior analyses of cardiac conduction. Most previous genome-wide association studies involved the study of common genetic variation in smaller samples of up to 28,517 individuals.^{8,10,11} In keeping with those prior studies, we again observed that *SCN10A* is the most prominent gene involved in atrioventricular conduction. Our recent GWAS based on 105K samples corroborates many of our current findings.³⁴ However, our current study had greater power than those earlier analyses for assessment of rare coding variation.

Our study has two major implications. First, our results underscore the utility of assessing coding variation as an efficient way to identify functional molecular domains. In particular, our findings provide insights into the functional topology of *SCN10A*. The *SCN10A* sodium channel gene is widely expressed in the nervous system and heart,²¹ but it has only recently been implicated in cardiac conduction^{8,34–36} and arrhythmias such as AF³⁵ and Brugada syndrome.³⁷ *SCN10A* encodes an alpha subunit (with six transmembrane spanning regions), which forms tetrameric, voltage gated sodium channels responsible for the Nav 1.8 late sodium channel current.^{38,39} We found a collection of amino acid substitutions in the linker region between the second and third domains of *SCN10A* that were associated with PR duration (Figure 2). Variants in this linker region that were associated with the PR interval also were associated with AF, suggesting that function of this domain may have important clinical implications.

Prior work on the homologous *SCN5A* cardiac sodium channel gene – which is also a cardiac conduction locus – indicates that this linker region is critical for sodium channel inactivation. Sodium influx is predominantly responsible for cardiomyocyte depolarization. Moreover, channel inactivation is essential for restoration of the hyperpolarized state needed for cyclic cardiomyocyte depolarization and contraction. Therefore, variations in this linker region might be involved in Nav 1.8 inactivation. Other data are necessary to identify relationships among variation in the linker region, the late sodium channel current, and channel inactivation in both healthy and diseased states.

Together with previously discovered susceptibility genes, our findings implicate genes in different functional classes that regulate atrioventricular conduction such as ion channels and cardiac transcription factors. In many cases, anomalies in these genes have been found to cause human cardiac diseases, such as congenital heart defects, primary cardiac conduction abnormalities, and syndromes predisposing to sudden cardiac death (Supplementary Table 3). Interestingly, some of the genes are not expressed (in high abundance) in the right atrial appendage or the left ventricle, according to existing data sets – although most are active in the heart (Supplementary Table 13). Atrioventricular nodal conduction also can be

influenced by external tone from the autonomic nervous system. Therefore, further work is necessary to determine the mechanisms by which identified genes that are not expressed in the heart influence the PR interval.

We acknowledge several limitations of our study. Because PR interval was measured across many cohorts, it is possible that there is some heterogeneity that would diminish our power to detect modest associations. We excluded individuals with extreme values of PR interval, which might have been gleaned from large variations in cardiac conduction. We also performed inverse normal transformation on the raw PR interval to reduce the heterogeneity, which on the other hand might reduce the interpretability. Although we performed single-variant and gene-based tests, we did not examine the association of haplotype patterns with PR interval, so it is unclear if there are any haplotypes that might be associated with PR interval. Most of the genetic variants analyzed were in exons. Therefore the effects of variants within regulatory regions were not investigated. We note that the variants identified may not be causally related to the studied phenotypes (PR interval, AF, and PWI), but may be in LD with causal variants. We anticipate that future increases in sample size with additional replications and more comprehensive genotyping platforms, such as denser SNP arrays or genome sequencing, will help address these limitations.

In conclusion, we studied genetic variants associated with PR interval duration and identified 31 common loci – including 11 that were novel – and two rare variant regions. Our findings greatly expand our knowledge of the genes that underlie atrioventricular conduction in the heart.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Honghuang Lin, PhD^{1,2}, Jessica van Setten, PhD³, Albert V Smith, PhD^{4,5}, Nathan A Bihlmeyer, BS⁶, Helen R. Warren, PhD^{7,8}, Jennifer A Brody, BA⁹, Farid Radmanesh, MD, MPH¹⁰, Leanne Hall, MSc^{11,12}, Niels Grarup, MD, PhD¹³, Martina Müller-Nurasvid, PhD^{14,15,16}, Thibaud Boutin, PhD¹⁷, Niek Verweij, MSc¹⁸, Henry J. Lin, MD¹⁹, Ruifang Li-Gao, MSc²⁰, Marten E. van den Berg, MSc²¹, Jonathan Marten, MSc¹⁷, Stefan Weiss, PhD^{22,23}, Bram Prins, PhD, Jeffrey Haessler, MS²⁴, Leo-Pekka Lyytikäinen, MD²⁵, Hao Mei, PhD²⁶, Tamara B. Harris, MD²⁷, Lenore J. Launer, PhD²⁷, Man Li, PhD²⁸, Alvaro Alonso, MD, PhD²⁹, Elsayed Z Soliman, MD, MSc³⁰, John M. Connell, MD, PhD³¹, Paul L Huang, MD, PhD³², Lu-Chen Weng, PhD^{32,33}, Heather S Jameson, PhD³², William Hucker, MD, PhD³², Alan Hanley, MD³², Nathan R Tucker, PhD³², Yii-Der Ida Chen, PhD¹⁹, Joshua C. Bis, PhD⁹, Kenneth M. Rice, PhD³⁴, Colleen M. Sitlani, PhD⁹, Jan A. Kors, PhD³⁵, Zhijun Xie, MD, PhD³⁶, Chengping Wen, MD, PhD³⁶, Jared W Magnani, MD, ScM³⁷, Christopher P Nelson, PhD^{11,12}, Jørgen K. Kanters, MD, PhD³⁸, Moritz F. Sinner, MD, MPH^{14,15}, Konstantin Strauch, PhD^{16,39}, Annette Peters, PhD^{15,40,41}, Melanie Waldenberger, PhD^{40,42}, Thomas Meitinger, MD^{15,43,44}, Jette Bork-Jensen, PhD¹³,

Oluf Pedersen, MD, DMSc¹³, Allan Linneberg, MD, PhD^{45,46,47}, Igor Rudan, MD, PhD⁴⁸, Rudolf A. de Boer, MD, PhD¹⁸, Peter van der meer, MD, PhD¹⁸, Jie Yao, MS¹⁹, Xiuqing Guo, PhD¹⁹, Kent D. Taylor, PhD¹⁹, Nona Sotoodehnia, MD, MPH⁴⁹, Jerome I. Rotter, MD¹⁹, Dennis O. Mook-Kanamori, MD, PhD²⁰, Stella Trompet, PhD⁵⁰, Fernando Rivadeneira, MD, PhD⁵¹, André Uitterlinden, PhD⁵², Mark Eijgelsheim, MD, PhD⁵³, Sandosh Padmanabhan, MD⁵⁴, Blair H. Smith, MD⁵⁵, Henry Völzke, MD^{23,56}, Stephan B. Felix, MD^{23,57}, Georg Homuth, PhD²², Uwe Völker, PhD^{22,23}, Massimo Mangino, PhD⁵⁸, Timothy D Spector, MB, MSc, MD, FRCP⁵⁸, Michiel L. Bots, MD, PhD⁵⁹, Marco Perez, MD⁶⁰, Mika Kähönen, MD, PhD⁶¹, Olli T. Raitakari, MD, PhD⁶², Vilmundur Gudnason, MD^{4,5}, Dan E Arking, PhD⁶³, Patricia B Munroe, PhD^{7,8}, Bruce M Psaty, MD, PhD^{64,65}, Cornelia M. van Duijn, MD, PhD⁶⁶, Emelia J. Benjamin, MD, ScM^{2,67}, Jonathan Rosand, MD, MSc¹⁰, Nilesh J Samani, MD^{11,12}, Torben Hansen, MD, PhD¹³, Stefan Kääb, MD, PhD^{14,15}, Ozren Polasek, MD, PhD⁶⁸, Pim van der Harst, MD, PhD¹⁸, Susan R. Heckbert, MD, PhD^{65,69}, J. Wouter Jukema, MD, PhD⁵⁰, Bruno H Stricker, MD, PhD⁵³, Caroline Hayward, PhD¹⁷, Marcus Dörr, MD^{23,57}, Yalda Jamshidi, PhD, FRSB⁷⁰, Folkert W. Asselbergs, MD, PhD^{3,71,72}, Charles Kooperberg, PhD²⁴, Terho Lehtimäki, MD, PhD²⁵, James G. Wilson, PhD⁷³, Patrick T. Ellinor, MD, PhD^{32,33,*}, Steven A. Lubitz, MD, MPH^{32,33,*}, and Aaron Isaacs, PhD^{74,*}

Affiliations

¹Section of Computational Biomedicine, Dept of Medicine, Boston University School of Medicine, Boston ²National Heart Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, MA ³Dept of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht, the Netherlands ⁴Icelandic Heart Association, Kopavogur ⁵Faculty of Medicine, University of Iceland, Reykjavik, Iceland ⁶Predoctoral Training Program in Human Genetics, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD ⁷William Harvey Research Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK ⁸NIHR Barts Cardiovascular Research Unit, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK ⁹Cardiovascular Health Research Unit, Dept of Medicine, University of Washington, Seattle, WA ¹⁰Massachusetts General Hospital, Center for Human Genetic Research, Broad Institute of Harvard and MIT, Cambridge, MA ¹¹Dept of Cardiovascular Sciences, University of Leicester ¹²NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, UK ¹³The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark ¹⁴Dept of Medicine I, University Hospital Munich, Biometry and Epidemiology, Chair of Genetic Epidemiology, Ludwig-Maximilians-Universität ¹⁵DZHK (German Cardiovascular Research Centre), partner site: Munich Heart Alliance, Munich ¹⁶Institute of Genetic Epidemiology, Helmholtz Zentrum München -German Research Center for Environmental Health, Neuherberg, Germany ¹⁷Medical Research Council Human Genetics Unit, Institute of Genetics and

Molecular Medicine, University of Edinburgh, Edinburgh, UK ¹⁸University Medical Center Groningen, University of Groningen, Dept of Cardiology, the Netherlands ¹⁹The Institute for Translational Genomics and Population Sciences & Dept of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA ²⁰Dept of Clinical Epidemiology, Leiden University Medical Center, Leiden ²¹Dept of Medical Informatics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands ²²Interfaculty Institute for Genetics and Functional Genomics, University Medicine and Ernst-Moritz-Arndt-University Greifswald ²³DZHK (German Cardiovascular Research Centre), partner site Greifswald, Germany ²⁴Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA ²⁵Dept of Clinical Chemistry, Fimlab Laboratories and Faculty of Medicine and Life Sciences, Tampere University Hospital and Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland ²⁶Dept of Data Science, University of Mississippi Medical Center, Jackson, MS ²⁷Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Intramural Research Program, National Institutes of Health, Bethesda, MD ²⁸Division of Nephrology & Hypertension, Internal Medicine, School of Medicine, University of Utah, Salt Lake City, UT ²⁹Dept of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA ³⁰Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston Salem, NC ³¹Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK ³²Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA ³³Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA ³⁴Dept of Biostatistics, University of Washington, Seattle, WA ³⁵Dept of Medical Informatics, Dept of Epidemiology, ErasmusMC, Rotterdam, the Netherlands ³⁶TCM Clinical Basis Institute, Zhejiang Chinese Medicine University, Hangzhou, Zhejiang, China ³⁷Division of Cardiology, Dept of Medicine, UPMC Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, PA ³⁸Laboratory of Experimental Cardiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark ³⁹Institute of Medical Informatics, Biometry and Epidemiology, Chair of Genetic Epidemiology, Ludwig-Maximilians-Universität ⁴⁰Institute of Epidemiology II, Helmholtz Zentrum München -German Research Center for Environmental Health, Neuherberg, Germany ⁴¹German Center for Diabetes Research, Neuherberg ⁴²Research unit of Molecular Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany ⁴³Institute of Human Genetics, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany ⁴⁴Institute of Human Genetics, Technische Universität München, Munich, Germany ⁴⁵Research Centre for Prevention and Health, Capital Region of Denmark, Copenhagen ⁴⁶Dept of Clinical Experimental Research, Rigshospitalet, Denmark ⁴⁷Dept of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark ⁴⁸Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK ⁴⁹Cardiovascular Health Research Unit, Division of Cardiology, Depts of Medicine

and Epidemiology, University of Washington, Seattle, WA ⁵⁰Dept of Cardiology, Leiden University Medical Center, Leiden ⁵¹Human Genomics Facility, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands ⁵²Human Genotyping Facility, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands ⁵³Dept of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands ⁵⁴British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow ⁵⁵Division of Population Health Sciences, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK ⁵⁶Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany ⁵⁷Dept of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany ⁵⁸Dept of Twin Research and Genetic Epidemiology, King's College London, London, UK ⁵⁹Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands ⁶⁰Division of Cardiovascular Medicine, Dept of Medicine, Stanford University School of Medicine, Stanford, CA ⁶¹Dept of Clinical Physiology, Tampere University Hospital and Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland ⁶²Dept of Clinical Physiology and Nuclear Medicine, Turku University Hospital, and Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland ⁶³McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD ⁶⁴Cardiovascular Health Research Unit, Depts of Medicine, Epidemiology and Health Services, University of Washington, Seattle, WA 65 Kaiser Permanente Washington Health Research Institute, Kaiser Foundation Health Plan of Washington, Seattle, WA ⁶⁶Genetic Epidemiology Unit, Dept of Epidemiology, ErasmusMC, Rotterdam, the Netherlands ⁶⁷Section of Cardiovascular Medicine, Dept of Medicine, Boston University School of Medicine, Boston ⁶⁸Faculty of Medicine, University of Split, Split, Croatia ⁶⁹Cardiovascular Health Research Unit & Dept of Epidemiology, University of Washington, Seattle, WA ⁷⁰Cardiogenetics Lab, Genetics and Molecular Cell Sciences Research Centre, Cardiovascular and Cell Sciences Institute, St George's, University of London, Cranmer Terrace, London, UK ⁷¹Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, the Netherlands ⁷²Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London, UK 73Physiology & Biophysics, University of Mississippi Medical Center, Jackson, MS 74CARIM School for Cardiovascular Diseases, Maastricht Centre for Systems Biology (MaCSBio) & Dept of Biochemistry, Maastricht University, Maastricht, the Netherlands

Acknowledgments

Sources of Funding: This work was partly supported by grants from the National Institutes of Health to Drs. Ellinor, Benjamin, and Lunetta (2RO1HL092577), Ellinor and Benjamin (R01HL128914), Ellinor (K24HL105780), and Arking and Sotoodehnia (R01HL116747). Dr. Ellinor is also supported by an Established Investigator Award from the American Heart Association (13EIA14220013) and by the Fondation Leducq (14CVD01). Dr. Lin was partly supported by Boston University Digital Health Initiative, and the National Center for Advancing Translational Sciences, National Institutes of Health, through BU-CTSI Grant Number 1UL1TR001430. Niek

Verweij is supported by ICIN-NHI and Marie Sklodowska-Curie GF (call: H2020-MSCA-IF-2014, Project ID: 661395). Dr. Lubitz is supported by NIH grants K23HL114724 and a Doris Duke Charitable Foundation Clinical Scientist Development Award 2014105. Dr. Sotoodehnia is supported by NIH grants HL116747 and HL111089. Folkert W. Asselbergs is supported by a Dekker scholarship-Junior Staff Member 2014T001 – Netherlands Heart Foundation and UCL Hospitals NIHR Biomedical Research Centre. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services.

Disclosures: Dr. Patrick Ellinor is PI of a grant from Bayer HealthCare to the Broad Institute focused on the genetics and therapeutics of AF. Dr. Bruce Psaty serves on the DSMB of a clinical trial funded by the manufacturer (Zoll LifeCor) and on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. Dr. Lubitz receives sponsored research support from Bayer HealthCare, Biotronik, and Boehringer Ingelheim, and has consulted for St. Jude Medical and Quest Diagnostics.

References

- Soliman EZ, Prineas RJ, Case LD, Zhang ZM, Goff DC Jr. Ethnic distribution of ecg predictors of atrial fibrillation and its impact on understanding the ethnic distribution of ischemic stroke in the atherosclerosis risk in communities (aric) study. Stroke; a journal of cerebral circulation. 2009; 40:1204–1211.
- Cheng S, Keyes MJ, Larson MG, McCabe EL, Newton-Cheh C, Levy D, et al. Long-term outcomes in individuals with prolonged pr interval or first-degree atrioventricular block. JAMA. 2009; 301:2571–2577. [PubMed: 19549974]
- Xiao HB, Roy C, Fujimoto S, Gibson DG. Natural history of abnormal conduction and its relation to prognosis in patients with dilated cardiomyopathy. Int J Cardiol. 1996; 53:163–170. [PubMed: 8682602]
- Thiene G, Pennelli N, Rossi L. Cardiac conduction system abnormalities as a possible cause of sudden death in young athletes. Human pathology. 1983; 14:704–709. [PubMed: 6873936]
- 5. Pilia G, Chen WM, Scuteri A, Orru M, Albai G, Dei M, et al. Heritability of cardiovascular and personality traits in 6,148 sardinians. PLoS Genet. 2006; 2:e132. [PubMed: 16934002]
- Silva CT, Kors JA, Amin N, Dehghan A, Witteman JC, Willemsen R, et al. Heritabilities, proportions of heritabilities explained by gwas findings, and implications of cross-phenotype effects on pr interval. Hum Genet. 2015; 134:1211–1219. [PubMed: 26385552]
- Newton-Cheh C, Guo CY, Wang TJ, O'Donnell CJ, Levy D, Larson MG. Genome-wide association study of electrocardiographic and heart rate variability traits: The framingham heart study. BMC Med Genet. 2007; 8(Suppl 1):S7. [PubMed: 17903306]
- 8. Pfeufer A, van Noord C, Marciante KD, Arking DE, Larson MG, Smith AV, et al. Genome-wide association study of pr interval. Nat Genet. 2010; 42:153–159. [PubMed: 20062060]
- Holm H, Gudbjartsson DF, Arnar DO, Thorleifsson G, Thorgeirsson G, Stefansdottir H, et al. Several common variants modulate heart rate, pr interval and qrs duration. Nat Genet. 2010; 42:117–122. [PubMed: 20062063]
- Butler AM, Yin X, Evans DS, Nalls MA, Smith EN, Tanaka T, et al. Novel loci associated with pr interval in a genome-wide association study of 10 african american cohorts. Circ Cardiovasc Genet. 2012; 5:639–646. [PubMed: 23139255]
- Smith JG, Magnani JW, Palmer C, Meng YA, Soliman EZ, Musani SK, et al. Genome-wide association studies of the pr interval in african americans. PLoS Genet. 2011; 7:e1001304. [PubMed: 21347284]
- Grove ML, Yu B, Cochran BJ, Haritunians T, Bis JC, Taylor KD, et al. Best practices and joint calling of the humanexome beadchip: The charge consortium. PLoS ONE. 2013; 8:e68095. [PubMed: 23874508]
- Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA, et al. Optimal unified approach for rare-variant association testing with application to small-sample case-control wholeexome sequencing studies. American journal of human genetics. 2012; 91:224–237. [PubMed: 22863193]

- Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. American journal of human genetics. 2011; 89:82– 93. [PubMed: 21737059]
- Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using polyphen-2. Current protocols in human genetics/editorial board, Jonathan L. Haines ... [et al.]. 2013 Chapter 7: Unit7 20.
- 16. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the sift algorithm. Nature protocols. 2009; 4:1073–1081. [PubMed: 19561590]
- Christophersen IE, Rienstra M, Roselli C, Yin X, Geelhoed B, Barnard J, et al. Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. Nat Genet. 2017; 49:946–952. [PubMed: 28416818]
- Christophersen IE, Magnani JW, Yin X, Barnard J, Weng LC, Arking DE, et al. Fifteen genetic loci associated with the electrocardiographic p wave. Circ Cardiovasc Genet. 2017; 10
- Segre AV, Consortium D, investigators M. Groop L, Mootha VK, Daly MJ, et al. Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. PLoS Genet. 2010; 6
- Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B (Methodological). 1995; 57:289–300.
- 21. Consortium GT. Human genomics. The genotype-tissue expression (gtex) pilot analysis: Multitissue gene regulation in humans. Science. 2015; 348:648–660. [PubMed: 25954001]
- ENCODE Project Consortium. Dunham I, Kundaje A, Aldred SF, Collins PJ, Davis CA, et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012; 489:57–74. [PubMed: 22955616]
- Chadwick LH. The nih roadmap epigenomics program data resource. Epigenomics. 2012; 4:317– 324. [PubMed: 22690667]
- Ahmed M, Sallari RC, Guo H, Moore JH, He HH, Lupien M. Variant set enrichment: An r package to identify disease-associated functional genomic regions. BioData mining. 2017; 10:9. [PubMed: 28239419]
- McNair WP, Ku L, Taylor MR, Fain PR, Dao D, Wolfel E, et al. Scn5a mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation. 2004; 110:2163–2167. [PubMed: 15466643]
- Olson TM, Michels VV, Ballew JD, Reyna SP, Karst ML, Herron KJ, et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA. 2005; 293:447–454. [PubMed: 15671429]
- 27. Chen L, Zhang W, Fang C, Jiang S, Shu C, Cheng H, et al. Polymorphism h558r in the human cardiac sodium channel scn5a gene is associated with atrial fibrillation. The Journal of international medical research. 2011; 39:1908–1916. [PubMed: 22117993]
- Qureshi SF, Ali A, John P, Jadhav AP, Venkateshwari A, Rao H, et al. Mutational analysis of scn5a gene in long qt syndrome. Meta gene. 2015; 6:26–35. [PubMed: 26401487]
- 29. Iwasa H, Itoh T, Nagai R, Nakamura Y, Tanaka T. Twenty single nucleotide polymorphisms (snps) and their allelic frequencies in four genes that are responsible for familial long qt syndrome in the japanese population. Journal of human genetics. 2000; 45:182–183. [PubMed: 10807545]
- 30. Modell SM, Lehmann MH. The long qt syndrome family of cardiac ion channelopathies: A huge review. Genet Med. 2006; 8:143–155. [PubMed: 16540748]
- Ter Bekke RMA, Isaacs A, Barysenka A, Hoos MB, Jongbloed JDH, Hoorntje JCA, et al. Heritability in a scn5a-mutation founder population with increased female susceptibility to nonnocturnal ventricular tachyarrhythmia and sudden cardiac death. Heart Rhythm. 2017; 14:1873– 1881. [PubMed: 28782696]
- 32. Granados-Riveron JT, Ghosh TK, Pope M, Bu'Lock F, Thornborough C, Eason J, et al. Alphacardiac myosin heavy chain (myh6) mutations affecting myofibril formation are associated with congenital heart defects. Hum Mol Genet. 2010; 19:4007–4016. [PubMed: 20656787]

- Posch MG, Waldmuller S, Muller M, Scheffold T, Fournier D, Andrade-Navarro MA, et al. Cardiac alpha-myosin (myh6) is the predominant sarcomeric disease gene for familial atrial septal defects. PLoS ONE. 2011; 6:e28872. [PubMed: 22194935]
- 34. van Setten, J., Brody, JA., Jamshidi, Y., Swenson, BR., Butler, AM., Campbell, H., et al. Genomewide association meta-analysis of pr interval identifies 47 novel loci associated with atrial and atrioventricular electrical activity. bioRxiv. DOI: https://doi.org/10.1101/241489
- 35. Chambers JC, Zhao J, Terracciano CM, Bezzina CR, Zhang W, Kaba R, et al. Genetic variation in scn10a influences cardiac conduction. Nat Genet. 2010; 42:149–152. [PubMed: 20062061]
- Sotoodehnia N, Isaacs A, de Bakker PI, Dorr M, Newton-Cheh C, Nolte IM, et al. Common variants in 22 loci are associated with qrs duration and cardiac ventricular conduction. Nat Genet. 2010; 42:1068–1076. [PubMed: 21076409]
- 37. Bezzina CR, Barc J, Mizusawa Y, Remme CA, Gourraud JB, Simonet F, et al. Common variants at scn5a-scn10a and hey2 are associated with brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet. 2013; 45:1044–1049. [PubMed: 23872634]
- Yang T, Atack TC, Stroud DM, Zhang W, Hall L, Roden DM. Blocking scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circ Res. 2012; 111:322–332. [PubMed: 22723299]
- 39. Verkerk AO, Remme CA, Schumacher CA, Scicluna BP, Wolswinkel R, de Jonge B, et al. Functional nav1.8 channels in intracardiac neurons: The link between scn10a and cardiac electrophysiology. Circ Res. 2012; 111:333–343. [PubMed: 22723301]

Clinical Perspective

The duration of PR interval is an important biomarker of the cardiac conduction system. Increasing evidences suggest that cardiac conduction measurements including PR interval are heritable. It is thus interesting to understand the biological and potential clinical implications of genetic variation underlying cardiac conduction. We performed a large-scale meta-analysis of PR interval that included 83,367 participants of European ancestry and 9,436 of African ancestry using the Illumina exome chip. Thirty-one genetic loci were significantly associated with PR interval after Bonferroni correction, including 11 loci that have not been previously reported. Our findings provide new insights to the current understanding of atrioventricular conduction, which is critical for cardiac activity and an important determinant of health.

Lin et al.




Figure 1. Manhattan plot showing the association between common variants and PR interval from combined ancestry analysis

The x-axis represents the chromosomal position for each SNP, and the y-axis represents the $-\log_{10}(p\text{-value})$ of the association with PR interval. The dashed line represents the genome-wide significance cutoff of 5×10^{-8} , and the blue line represents the Bonferroni *P*-value cutoff of 1.3×10^{-6} . Black color represents known loci, whereas red color represents novel loci.




Figure 2. Diagram of sodium voltage-gated channel alpha subunit 10 (SCN10A) Each yellow circle represents a genetic variant with a *P*-value less than the significance cutoff (1.2×10^{-6}) . Each red circle represents a genetic variant with a *P*-value greater than the significance cutoff, but less than 0.05.

NH,

Voltage sensor

COOH

Transmembrane

● Variant with $P \le 1.2 \times 10^{-6}$ ● Variant with $P \le 0.05$

domain

Author	
Manuscript	

Author Manuscript

studies
ating
particip
of the J
l characteristics of the participating st
Clinical

_ * <u>s</u>	~			Ŧ			Ŧ							Ŧ											-
Calcium antagonists (%)	108 (5.3)	176 (1.8)	18 (2.1)	Excluded	206 (6.3)	25 (2.5)	Excluded	ND	ND	ND	13 (0.5)	6 (2.0)	23 (1.2)	Excluded	ND	ND	ND	ND	ND	18 (1.0)	1230 (9.3)	1 (0.1)	222 (6.6)	60 (9.6)	Excluded
Diuretics (%)	ΟN	1085 (11.0)	260 (30.9)	ΠN	750 (23.1)	133 (13.5)	ΠN	ΠN	QN	QN	152 (5.8)	3 (1.0)	39 (2.0)	ΠN	ΟN	ΠN	ΠN	ΠN	ND	32 (1.8)	1715 (13.3)	24 (1.3)	717 (21.3)	217 (34.6)	QN
Beta blockers (%)	635 (31.0)	789 (8.0)	248 (29.5)	Excluded	366 (11.3)	3 (0.3)	Excluded	Excluded	39 (2.2)	QN	199 (7.6)	8 (2.7)	64 (3.3)	Excluded	Excluded	293 (12.4)	192 (2.1)	ND	ND	69 (4.6)	735 (5.5)	38 (2.1)	315 (9.4)	54 (8.6)	Excluded
SBP, mmHg, mean ± SD	143 ± 20	118±17	153 ± 24	ND	136±21	140 ± 20	119 ± 15	N/A	128±19	130 ± 18	127±19	139 ± 14	122±16	123 ± 21	133±17	ND	134 ± 18	131 ± 20	119 ± 16	125±17	130 ± 18	119 ± 14	128 ± 22	142 ± 22	126±18
Height, cm, mean ± SD	166±9	169 ± 9	166 ± 9	171 ± 10	165±9	$168{\pm}10$	$169{\pm}10$	$169{\pm}10$	171±9	172±9	168 ± 9	168 ± 9	175±9	$169{\pm}10$	$174{\pm}10$	168 ± 9	168 ± 10	170±9	163±7	175±10	162±6	172±9	168 ± 9	165±9	169 ± 9
BMI, kg/m2, mean ± SD	27.0±4.4	26.9 ± 4.7	27.5±3.8	28.5±5.8	26.4± 4.4	26.9 ± 4.6	26.0 ± 5.0	26.1 ± 4.6	26.1 ± 4.6	26.3±4.6	26.9 ± 4.4	28.0 ± 4.3	25.9 ± 4.5	27.8±5.1	30.0 ± 4.8	26.3±3.6	26.9 ± 5.1	27.5±5.0	26.8 ± 5.4	24.9 ± 3.9	28.7±5.6	26.4 ± 4.9	29.4 ± 6.1	28.4± 5.5	31.4 ± 6.4
RR interval, ms, mean± SD	895±129	928±136	960±169	926±166	956±151	982±159	910±175	913±173	934±145	921±150	944±149	929±127	896±145	1047±158	940±151	871±144	886±146	897±146	923±148	950±151	921±138	1028 ± 165	929±151	918±161	956±150
PR interval, ms, mean± SD	170.5 ± 26.8	160.3 ± 23.3	161.1 ± 19.9	163.0 ± 26.8	167.8 ± 28.2	152.9 ± 23.2	152.0 ± 22.1	167.6±27.7	153.0 ± 24.0	158.2 ± 22.4	162.1 ± 22.2	159.8 ± 24.0	156.7±24.7	164.7 ± 25.2	164.5 ± 23.4	168.2±24.7	164.1 ± 24.9	158.5 ± 23.3	159.6 ± 22.6	155.9 ± 22.5	161.4 ± 24.0	156.2 ± 22.6	171.2 ± 26.8	170.2 ± 28.1	172.7 ± 27.3
Age, yrs, mean	75.9±5.4	54.1±5.7	57.6±10.7	60.7±11.6	72.4±5.4	48.2±14.3	39.3±9.8	73.2±8.2	39.1±14.5	46.1 ± 7.9	48.3±13.0	55.0±13.4	45.2±13.1	62.8±10.2	55.9±5.9	68.6 ± 8.1	52.0±13.6	49.2±15.3	52.3±11.7	39.1±13.0	66.0±6.5	41.9 ± 5.0	53.3±5.8	72.4±5.5	52.7±12.5
Men, N (%)	742 (36.2)	4528 (46.1)	324 (38.9)	1394 (55.9)	1313 (40.4)	447 (45.5)	3428 (45.2)	161 (45.4)	893 (50.9)	2843 (48.7)	1247 (47.6)	106 (36.2)	781 (40.3)	1171 (47.7)	2717 (47.0)	1086 (46.1)	3786 (41.3)	2608 (40.2)	32 (6.9)	779 (44.9)	0 (0)	824 (44.6)	1291 (38.4)	232 (37.0)	833 (37.5)
Total N	2052	9828	841	2493	3247	982	7580	355	1755	5836	2617	293	1934	2455	5782	2358	9168	6493	465	1735	13252	1846	3366	627	2220
Study	AGES	ARIC	BRIGHT	CAMP	CHS	ERF	SHF	GOCHA	GRAPHIC	INTER99	KORA	KORCULA	LifeLines	MESA	NEO	RS	GS:SFHS	SHIP	TwinsUK	UHP	IHM	YFS	ARIC	CHS	SHſ
Ancestry												European ancesu y												African ancestry	

Ancestry	Study	Total N Men, N	Men, N (%)	Age, yrs, mean	PR interval, ms, mean± SD	RR interval, ms, mean± SD	BMI, kg/m2, mean ± SD	Height, cm, mean ± SD	SBP, mmHg, mean ± SD	Beta blockers (%)	Diuretics (%)	Calcium antagonists* (%)
	MESA	1565	718 (45.9)	62.3 ± 10.0	170.9 ± 26.3	1050±172	30.2 ± 5.9	168 ± 10	132 ± 21	Excluded	ΠN	Excluded
	IHM	1658	0 (0)	64.6±6.4	64.6±6.4 167.1± 24.8	921±148	31.1±5.8	162 ± 7	134 ± 17	87 (5.2)	393 (23.7)	341 (20.6)

Exclusion criteria are given in Supplementary Table 1. SBP, systolic blood pressure; BMI, body mass index; ND, not determined; SD, standard deviation;

* Non-dihydropyridine calcium antagonists.

Circ Genom Precis Med. Author manuscript; available in PMC 2019 May 01.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Author N
Manuscrip
pt
Au
Author Manuscrip
nuscript

Author Manuscript

2	
Ð	
Q	
ц	

s	
die	
stu	
all	
of	
sis	
alys	
ana	
sta-2	
me	
rom meta-analysis	
fre	
val	
nter	
S in	
ח PR	
vith	
ρ	
iate	
i o ci	
ass	
ficantly asso	
can	
nifi	
igi	
ts	
mon variants signif	
var	
uo	
um	
Con	
\cup	

3p22.2 $SCNI0A$ Missense $3p22.2$ $SCN5A$ Intronic $7q31.2$ $CAV1$ Intronic $4q21.23$ $ARHGAP24$ Intronic $4q21.23$ $ARHGAP24$ Intronic $4q21.23$ $ARHGAP24$ Intronic 9 $2p14$ $MEISI$ Intronic $12q24.21$ $IBX3$ Integenic $12q24.21$ $IBX5$ $3'UTR$ 56 $3p22.2$ $DLEC1$ Missense $5q35.1$ $CRBRF$ Intergenic 6 $5q21.1$ PAM Missense $5q35.11$ RAM Missense $5q35.12$ $DLEC1$ Missense $5q32.23$ $SLC35F1$ Intergenic 6 $5q21.1$ PAM Missense $3p22.2$ $SLC22A14$ Missense $3p22.2$ $SLC22A14$ Missense $13q12.11$ $XPO4$ Intronic $2q31.2$ TTN Missense $1q22$ $SLC22A14$ Missense $1q24$ $ADPRHLIMissense1q22SLC22A14Missense1q24D12ID22q31.2SLC22A14Missense1q24ADPRHLIMissense1q24SPA11Missense1q24SPA11Missense1q24.2STPA11Missense1q24.3$	SNP	Locus	Closest gene	Function	Coding allele	CAF*	Beta	SE	P value	Number of studies [‡]	Prolong or shorten PR interval	Novel locus
3p22.2 $SCN55A$ Intronic $7q31.2$ $CAV1$ Intronic $4q21.23$ $ARHGAP24$ Intronic $12p12.1$ $LINC00477$ Intergenic $12p12.1$ $LINC00477$ Intergenic $12q24.21$ $TBX3$ Intergenic $12q24.21$ $TBX5$ $3'UTR$ $5q35.1$ $CRBRF$ Intergenic $5q35.1$ $CRBRF$ Intergenic $5q21.1$ PAM Missense $5q21.1$ PAM Missense $5q21.1$ PAM Missense $5q21.1$ PAM Missense $13q12.11$ $XP04$ Intergenic $2q31.2$ $TLC22A14$ Missense $13q12.11$ $XP04$ Intronic $13q22.2$ $SLC22A14$ Missense $13q12.11$ $XP04$ Intronic $13q23.4$ $ADPRHLI$ Missense $13q24$ $D122$ Intergenic $2q31.2$ TTN Missense $13q24$ $ADPRHLI$ Missense $13q24$ $ADPRHLI$ Missense $13q24$ $ADPRHLI$ Missense $1q22$ $STNPO2L$ Missense $1q24$ $STNPO2L$ Missense $1q23$ $CCDC141$ Missense $1q24$ $ADPRHLIMissense1q24ADPRHLIMissense1q24STMO2LMissense1q24STMO2LMissense1q24STMO2LMissense1q24STMILIMissense1q242STMILIMissense$	rs6795970	3p22.2	SCN10A	Missense	А	0.37	0.1705	0.0052	$4.0{ imes}10^{-240}$	27	Prolong	
7q31.2 $CAVI$ Intronic4q21.23 $ARHGAP24$ Intronic4q21.23 $ARHGAP24$ Intronic12p12.1 $LINC00477$ Intergenic2p14 $MEIS1$ Intronic12q24.21 $TBX3$ Intergenic12q24.21 $TBX5$ $3'UTR$ 5q35.1 $CREBRF$ Intergenic6 $3p22.2$ $DLECI$ $Missense$ $5q3.11$ $TBX5$ $3p22.2$ $SLC33FI$ Intergenic6 $3p22.2$ $SLC3414$ $Missense$ $3p22.2$ $3p22.2$ $SLC22A14$ $Missense$ $13q12.11$ $XPO4$ Intergenic $3p22.2$ $SLC22A14$ $Missense$ $3p22.2$ $SLC22A14$ $Missense$ $13q12.11$ $XPO4$ $Missense$ $13q12.11$ $XPO4$ $Missense$ $13q24$ $ADPRHLI$ $Missense$ $1q22$ $EFNAI$ $Missense$ $1q22$ $SYNPO2L$ $Missense$ $1q22$ $SYNPO2L$ $Missense$ $1q23$ $SRPAILI$ $Missense$ $1q24.3$ $MACFI$ $Missense$ $1q24.3$ $MACFI$ $Missense$ $1p34.3$ $MACFI$ $Missense$ $1p34.3$ $MACFI$ $Missense$ $1q22$ $SYMO2L$ $Missense$ $1q22$ $SYMO2L$ $Missense$ $1q24.3$ $MACFI$ $Missense$ $1p34.3$ MAC	rs3922844	3p22.2	SCN5A	Intronic	А	0.34	-0.1069	0.0053	$9.3{ imes}10^{-90}$	26	Shorten	
4q21.23 $ARHGAP24$ Intronic12p12.1 $LINC00477$ Intergenic2p14 $MEIS1$ Intronic12q24.21 $TBX3$ Intergenic12q24.21 $TBX5$ $3'UTR$ 5q35.1 $CREBRF$ Intergenic5q35.1 $CREBRF$ Intergenic5q31.1 BAM Missense5q21.1 PAM Missense3p22.2 $SLC35FI$ Intergenic5q21.1 PAM Missense3p22.2 $SLC35FI$ Intergenic2q31.2 TTN Missense13q12.11 $XPO4$ Intronic2q31.2 TTN Missense13q34 $ADPRHLI$ Missense13q34 $ADPRHLI$ Missense1q22 $EFNAI$ Missense1q22 $STNPO2L$ Missense1q23 $LINC00670$ Intronic1q24 $STPAILI$ Missense1q25 $STNPO2L$ Missense1q24 $STPAILI$ Missense1q25 $STPAILI$ Missense1q24 $STPAILI$ Missense1q25 $STPAILI$ Missense1q24 $STPAILI$ Missense1q25 $STPAILI$ Missense1q24 $STPAILI$ Missense1q25 $STPAILI$ Missense1q27 $STPAILI$ Missense1q28 $ADFI$ Missense1q29 $STPAILI$ Missense1q21 $ATTI$ Missense1q22 $STPAIII$ Missense1q24 $STAIII$	rs3807989	7q31.2	CAVI	Intronic	А	0.43	0.0908	0.0050	$3.0{\times}10^{-74}$	27	Prolong	
12p12.1LINC00477Intergenic $2p14$ MEIS1Intronic $2p14$ MEIS1Intronic $12q24.21$ TBX3Intergenic $12q24.21$ TBX53'UTR $5q35.1$ CREBRFMissense $5q35.1$ CREBRFIntergenic $6q22.31$ SLC35F1Intergenic $5q31.1$ PAMMissense $3p22.2$ SLC22A14Missense $3p22.2$ SLC22A14Missense $3p22.2$ SLC22A14Missense $13q12.11$ XPO4Intronic $2q31.2$ TTNMissense $13q34$ ADPRHL1Missense $1q22$ EFNA1Missense $1q22$ EFNA1Missense $1q22$ SYNP02LMissense $1q22$ STM1L1Intronic $1q23$ CDC141Missense $1q24.3$ SIPA1L1Missense $1q22$ SYNP02LMissense $1q23$ CDC141Missense $1q24.3$ MACF1Missense $1q24.3$ MACF1Missense $1q24.3$ SIPA1L1Intronic $4q35.2$ GJA1Missense $1p34.3$ MACF1Missense $1p34.3$ MAC	rs7660702	4q21.23	ARHGAP24	Intronic	C	0.33	-0.0921	0.0053	$1.2{ imes}10^{-68}$	27	Shorten	
$2p_{14}$ <i>MEIS1</i> Intronic $12q_{24.21}$ $TBX3$ Intergenic $12q_{24.21}$ $TBX5$ $3'UTR$ $5q_{35.1}$ $TBX5$ $3'UTR$ $5q_{35.1}$ $CREBRF$ Intergenic $5q_{35.1}$ $CREBRF$ Intergenic $5q_{35.1}$ $CREBRF$ Intergenic $5q_{31.1}$ PAM Missense $3p_{22.2}$ $SLC35F1$ Intergenic $3p_{22.2}$ $SLC35F1$ Intergenic $3p_{22.2}$ $SLC22A14$ Missense $13q_{12.11}$ $XPO4$ Intronic $13q_{12.11}$ $XPO4$ Missense $13q_{24.2}$ $SYNPO2L$ Missense $1q_{24.2}$ $SYNPO2L$ Missense $1q_{24.2}$ $STMALLI$ Missense $1q_{34.3}$ $MACFI$ Missense $1p_{34.3}$ </td <td>rs17287293</td> <td>12p12.1</td> <td>LINC00477</td> <td>Intergenic</td> <td>IJ</td> <td>0.14</td> <td>-0.1084</td> <td>0.0071</td> <td>$1.9{ imes}10^{-52}$</td> <td>27</td> <td>Shorten</td> <td></td>	rs17287293	12p12.1	LINC00477	Intergenic	IJ	0.14	-0.1084	0.0071	$1.9{ imes}10^{-52}$	27	Shorten	
12q24.21 TBX3 Intergenic 12q24.21 TBX5 3'UTR 5q35.1 DLECI Missense 5q35.1 CREBRF Intergenic 6 3p22.2 DLECI Missense 5q35.1 CREBRF Intergenic 6 5q2.31 SLC35F1 Intergenic 5q21.1 PAM Missense 3p22.2 SLC22A14 Missense 13q12.11 XPO4 Intronic 2q31.2 TTN Missense 13q42.11 XPO4 Intronic 2q31.2 TTN Missense 13q34 ADPRHLI Missense 1q22 EFNAI Missense 1q22 SIPARLI Missense 1q22 SIPALI Missense 1q24 LINC00670 Intronic 1q24 Missense Integenic 1q24 SIPALLI Missense 1q24 G31.2 CCDC141 Missense 1p34.3 MACFI Missense Intronic 1p34.3 MACFI	rs11897119	2p14	MEISI	Intronic	C	0.39	0.0566	0.0055	4.2×10^{-25}	25	Prolong	
12q24.21 <i>TBX5</i> 3'UTR 6 3p22.2 <i>DLEC1</i> Missense 5q35.1 <i>CREBRF</i> Intergenic 6q22.31 <i>SLC35F1</i> Intergenic 3p22.2 <i>SLC35F1</i> Intergenic 3p22.1 <i>PAM</i> Missense 3p22.2 <i>SLC35F1</i> Intergenic 3p22.2 <i>SLC35F1</i> Intergenic 3p22.2 <i>SLC22A14</i> Missense 13q12.11 <i>XPO4</i> Intronic 2q31.2 <i>TTN</i> Missense 13q34 <i>ADPRHL</i> Missense 1q22 <i>EFNA1</i> Missense 1q22 <i>SYNPO2L</i> Missense 1q22 <i>SYNPO2L</i> Missense 1q24 <i>ADPRHL1</i> Missense 1q25 <i>EFNA1</i> Missense 1q24 <i>SYNPO2L</i> Missense 1q24 <i>SYNPO2L</i> Missense 1q24.3 <i>SIPA1L1</i> Missense 1q24.3 <i>SIPA1L1</i> Missense 1q24.3 <i>SIPA1L1</i> Missense 1q35.3 <i>CCDC141</i>	rs1896312	12q24.21	TBX3	Intergenic	IJ	0.28	0.0564	0.0055	$8.7{ imes}10^{-25}$	26	Prolong	
63p22.2DLECIMissense5q35.1CREBRFIntergenic6q22.31SLC35F1Intergenic5q21.1PAMMissense3p22.2SLC22A14Missense13q12.11XPO4Intronic2q31.2TTNMissense13q34ADPRHL1Missense13q34ADPRHL1Missense13q34ADPRHL1Missense1q22EFNA1Missense1q22STNPO2LMissense1q22STNPO2LMissense1q23HATIMissense1q24SIPAILIIntronic1q25STNPO2LMissense1q24BATIMissense1q25SIPAILIMissense1q24SIPAILIIntronic1q25BATIMissense1q27CCDC141Missense1q28BATIMissense1q29BATIMissense1q21AATIMissense1q22SIPAILIMissense1q23CADC141Missense1q24AATIMissense1q24AATIMissense1q24AATIMissense1q24AATIMissense1q24AATIMissense1q24AATIMissense1q24AATIMissense1q24AATIMissense1q24AATIMissense1q24AATIMissense1q44AATIMissense1q44AATIM	rs883079	12q24.21	TBX5	3'UTR	IJ	0.29	0.0550	0.0054	4.5×10^{-24}	26	Prolong	
5q35.1CREBRFIntergenic6q22.31SLC35F1Intergenic5q21.1PAMMissense3p22.2SLC22A14Missense13q12.11XPO4Intronic2q31.2TTNMissense13q34ADPRHL1Missense1q22EFNA1Missense1q22EFNA1Missense1q22EFNA1Missense1q22EFNA1Missense1q22SYNP02LMissense1q24.2SIP41L1Intronic1q35.3CCDC141Missense1p34.3MACF1Missense1p34.3MissenseMissense	rs116202356	3p22.2	DLECI	Missense	А	0.02	-0.1953	0.0199	1.0×10^{-22}	27	Shorten	
6q22.31SLC35F1Intergenic5q21.1PAMMissense3p22.2SLC22A14Missense13q12.11XP04Intronic2q31.2TTNMissense2p25.1ID2Intergenic2p25.1ID2Intergenic2p25.1ID2Intergenic13q34ADPRHLIMissense1q22EFNAIMissense1q22STNPO2LMissense1q22STNPO2LMissense1q23FATIMissense1q24:2SIPAILIIntronic1q35:2FATIMissense1q24:3MACFIMissense1q25:1IntronicIntronic1q22:1ADFHLIIntronic1q22:1ADFTIMissense1q22:1ATTIMissense1q22:1ATTIMissense1q24:2SIPAILIMissense1q24:2SIPAILIMissense1q24:3MACFIMissense1p34:3MACFIMissense1p34:3ATFIIntronic4q22:1AFFIIntronic4q22:1AFFIIntronic4q23:3PIFCMissense	rs251253	5q35.1	CREBRF	Intergenic	Ū	0.42	-0.0439	0.0051	$4.7{ imes}10^{-18}$	26	Shorten	
5q21.1PAMMissense3p22.2SLC22A14Missense13q12.11XPO4Intronic2q31.2TTNMissense2q31.2TTNMissense2q31.2ID2Intergenic13q34ADPRHL1Missense1q22EFNA1Missense1q22EFNA1Missense1q22SYNPO2LIntronic1q22.2SYNPO2LMissense1q24.2SIPA1L1Intronic1q23.3MACF1Missense1q34.3MACF1Missense1p34.3MACF1Missense6q22.31GJA1Intergenic4q22.1AFF1Intergenic4q23.3PIFCMissense	rs11153730	6q22.31	SLC35F1	Intergenic	C	0.47	-0.0420	0.0049	$9.5{ imes}10^{-18}$	27	Shorten	Novel
3p22.2SLC22A14Missense13q12.11XPO4Intronic2q31.2TTNMissense2p25.1ID2Intergenic2p25.1ID2Intergenic2p25.1ID2Intergenic1q22EFVA1Missense1q22EFVA1Missense1q22SYNPO2LMissense1q22SYNPO2LMissense1q22STMP1L1Intronic1q22STMP1L1Intronic1q35.2FAT1Missense1p34.3MACF1Missense1p34.3MACF1Missense1p34.3MACF1Missense1p34.3MACF1Missense1p34.3AFF1Intergenic4q22.1AFF1Intergenic4q23.3D1FCMissense	rs35658696	5q21.1	PAM	Missense	IJ	0.04	0.0956	0.0119	$8.5{\times}10^{-16}$	27	Prolong	
97 13q12.11 XPO4 Intronic 95 2q31.2 TTN Missense 93 2p25.11 ID2 Intergenic 688 13q34 ADPRHL I Missense 688 13q34 ADPRHL I Missense 610 1q22 EFNA1 Missense 610 10q22.2 SYNPO2L Intronic 785 14q24.2 SIPA1L I Intronic 785 14q24.2 SIPA1L I Intronic 788 2q31.2 CCDC141 Missense 72 Ip34.3 MACF1 Missense 72 Ip34.3 MACF1 Missense 72 1p34.3 MACF1 Missense 73 6q22.31 GJA1 Intergenic 7 4q22.1 AFF1 Intergenic 7 4q22.1 AFF1 Intergenic 7 4q22.1 AFF1 Intergenic	rs2070492	3p22.2	SLC22A14	Missense	L	0.10	0.0624	0.0083	$4.0{ imes}10^{-14}$	27	Prolong	Novel
95 2q31.2 TTN Missense 93 2p25.1 <i>ID2</i> Intergenic 688 13q34 <i>ADPRHL</i> 1 Missense 688 13q34 <i>ADPRHL</i> 1 Missense 610 1q22 <i>EFVA1</i> Missense 610 10q22.2 <i>SYNPO2L</i> Missense 785 14q24.2 <i>SIPA1L1</i> Intronic 785 14q24.2 <i>SIPA1L1</i> Intronic 788 2q31.2 <i>CCDC141</i> Missense 588 2q31.2 <i>CCDC141</i> Missense 72 1p34.3 <i>MACF1</i> Missense 72 1p34.3 <i>MACF1</i> Missense 72 1p34.3 <i>MACF1</i> Missense 73 4q22.1 <i>AFF1</i> Intergenic 7 4q22.1 <i>AFF1</i> Intronic 7 4q23.1 <i>AFF1</i> Intronic	rs2585897	13q12.11	XPO4	Intronic	А	0.17	0.0471	0.0064	2.8×10^{-13}	27	Prolong	
93 2p25.1 ID2 Intergenic 688 13q34 ADPRHL I Missense 1q22 EFNA1 Missense 078 17p12 LINC00670 Intronic 610 10q22.2 SYNPO2L Missense 785 14q24.2 SIPA1L1 Intronic 785 14q24.2 SIPA1L1 Intronic 788 2q31.2 CCDC141 Missense 72 Ip34.3 MACF1 Missense 72 1p34.3 MACF1 Missense 73 4q22.1 AFF1 Missense 73 B34.3 MACF1 Missense 73 PAF1 Missense PAF1 7 4q22.1 AFF1 Intergenic 7 4q22.1 AFF1 Intergenic 7 AFF1 Missense Missense	rs2042995	2q31.2	NLL	Missense	С	0.26	0.0375	0.0057	$4.3{\times}10^{-11}$	27	Prolong	
688 13q34 ADPRHL I Missense 1q22 <i>EFNA1</i> Missense 078 17p12 <i>LINC00670</i> Intronic 610 10q22.2 <i>SYNP02L</i> Missense 785 14q24.2 <i>SIPA1L1</i> Intronic 785 14q24.2 <i>SIPA1L1</i> Intronic 788 2q31.2 <i>CCDC141</i> Missense 588 2q31.2 <i>CCDC141</i> Missense 72 1p34.3 <i>MACF1</i> Missense 72 4q22.1 <i>AFF1</i> Intergenic 7 4q22.1 <i>AFF1</i> Intronic 7 8642.31 <i>GJA1</i> Missense	rs4399693	2p25.1	D2	Intergenic	Α	0.34	0.0374	0.0058	9.1×10^{-11}	25	Prolong	
Iq22 <i>EFNA1</i> Missense 078 17p12 <i>LINC00670</i> Intronic 610 10q22.2 <i>SYNPO2L</i> Missense 785 14q24.2 <i>SIPA1L1</i> Intronic 785 14q24.2 <i>SIPA1L1</i> Intronic 785 14q24.2 <i>SIPA1L1</i> Intronic 788 2q31.2 <i>CCDC141</i> Missense 72 1p34.3 <i>MACF1</i> Missense 72 1p34.3 <i>MACF1</i> Missense 73 6q22.31 <i>GJA1</i> Intergenic 7 4q22.1 <i>AFF1</i> Intronic 7 8674.3 <i>D1FC</i> Missense	rs41306688	13q34	ADPRHL I	Missense	С	0.03	0.1002	0.0173	7.4×10^{-9}	22	Prolong	Novel
8 17p12 LINC00670 Intronic 0 10q22.2 SYNPO2L Missense 5 14q24.2 SIPA1L1 Intronic 4q35.2 FAT1 Missense 8 2q31.2 CCDC141 Missense 1p34.3 MACF1 Missense 6q22.31 GJA1 Intergenic 4q22.1 AFF1 Intergenic 8 2q31.3 DI FC	rs4745	1q22	EFNAI	Missense	F	0.49	0.0299	0.0053	1.2×10^{-8}	26	Prolong	
0 10q22.2 SYNPO2L Missense 5 14q24.2 <i>SIPA1L1</i> Intronic 4q35.2 <i>FAT1</i> Missense 8 2q31.2 <i>CCDC141</i> Missense 1p34.3 <i>MACF1</i> Missense 6q22.31 <i>GJA1</i> Integnic 4q22.1 <i>AFF1</i> Integnic 8 <i>PIFC</i> Missense	rs11078078	17p12	LINC00670	Intronic	Α	0.40	0.0281	0.0050	$2.2{ imes}10^{-8}$	27	Prolong	
 5 14q24.2 <i>SIPA1L1</i> Intronic 4q35.2 <i>FAT1</i> Missense 8 2q31.2 <i>CCDC141</i> Missense 1p34.3 <i>MACF1</i> Missense 6q22.31 <i>GJA1</i> Intergenic 4q22.1 <i>AFF1</i> Intronic 8o24.3 <i>PLFC</i> Missense 	rs60632610	10q22.2	SYNPO2L	Missense	Г	0.15	-0.0371	0.0068	4.5×10^{-8}	27	Shorten	Novel
4q35.2 <i>EAT1</i> Missense82q31.2 <i>CCDC141</i> Missense1p34.3 <i>MACF1</i> Missense6q22.31 <i>GJA1</i> Intergenic4q22.1 <i>AFF1</i> Intronic8o73.3 <i>PFFC</i> Missense	rs11848785	14q24.2	SIPAILI	Intronic	Ū	0.24	0.0317	0.0058	4.6×10^{-8}	27	Prolong	
8 2q31.2 <i>CCDC141</i> Missense 1p34.3 <i>MACF1</i> Missense 6q22.31 <i>GJA1</i> Intergenic 4q22.1 <i>AFF1</i> Intronic 8o24.3 <i>PFFC</i> Missense	rs3733414	4q35.2	FATI	Missense	А	0.38	0.0280	0.0051	$4.8{ imes}10^{-8}$	27	Prolong	
1p34.3MACFIMissense6q22.31GIA1Intergenic4q22.1AFFIIntronic8o24.3PI FCMissense	rs17362588	2q31.2	CCDC141	Missense	А	0.08	-0.0491	0600.0	$5.5{ imes}10^{-8}$	27	Shorten	Novel
6q22.31 <i>GIAI</i> Intergenic 4q22.1 <i>AFF1</i> Intronic 8o24.3 <i>DFFC</i> Missense	rs2296172	1p34.3	MACF1	Missense	ŋ	0.20	0.0326	0.0061	1.1×10^{-7}	27	Prolong	Novel
4q22.1 AFFI Intronic 8a243 DIFC Miscense	rs9398652	6q22.31	GIAI	Intergenic	А	0.14	0.0390	0.0074	1.3×10^{-7}	26	Prolong	Novel
8a24.3 <i>PLEC</i> Missense	rs442177	4q22.1	AFFI	Intronic	С	0.42	-0.0262	0.0050	1.8×10^{-7}	26	Shorten	Novel
ACTIVECTIVE OCTATE CONTRACT	rs7002002	8q24.3	PLEC	Missense	А	0.38	-0.0272	0.0052	$2.1{\times}10^{-7}$	25	Shorten	Novel

rs1768208 $3p22.1$ MOBP Intron T 0.25 0.0288 0.0057 3.6×10^{-7} 27 Prolong N rs2119788 4q34.1 HAND2 Intergenic C 0.52 -0.0246 0.0049 5.6×10^{-7} 27 Shorten N rs17391905 1p32.3 Clorf185 Intergenic G 0.03 -0.0694 0.0142 9.6×10^{-7} 27 Shorten N rs524295 10q24.1 ALDH18A1 Intergenic A 0.40 -0.0254 0.0053 9.7×10^{-7} 26 Shorten		TACUS	Closest gene	Function	Closest gene Function Coding allele ${ m CAF}^*$	CAF*	Beta	SE	P value	Number of studies ${}^{\sharp}$	Number of studies# Prolong or shorten PR interval Novel locus	Novel loci
HAND2 Intergenic C 0.52 -0.0246 0.0049 5.6×10^{-7} 27 Shorten Clarf185 Intergenic G 0.03 -0.0694 0.0142 9.6×10^{-7} 27 Shorten ALDH1841 Intergenic A 0.40 -0.0261 0.0053 9.7×10^{-7} 26 Shorten		3p22.1	MOBP	Intron	Т	0.25	0.0288	0.0057	3.6×10^{-7}	27	Prolong	Novel
<i>Clorf185</i> Intergenic G 0.03 -0.0694 0.0142 9.6×10^{-7} 27 <i>ALDH18A1</i> Intergenic A 0.40 -0.0261 0.0053 9.7×10^{-7} 26	rs2119788 4	łq34.1		Intergenic	C	0.52	-0.0246	0.0049	5.6×10^{-7}	27	Shorten	Novel
A 0.40 -0.0261 0.0053 9.7×10^{-7} 26	$rs17391905 $ ^{t^{-1}}	p32.3	Clorf185	Intergenic	IJ	0.03	-0.0694		9.6×10^{-7}	27	Shorten	
	rs524295 1	0q24.1	ALDH18A1	Intergenic	А	0.40	-0.0261	0.0053	$9.7{ imes}10^{-7}$	26	Shorten	

Author Manuscript

*
test
H
SKAT
Š
the
1 by
rval
inte
\mathbf{PR}
with
ed
iat
0Ci
ass
ns
) gene regions associated with
ē
ger
10
ď
Ē

Gene	P value	Qmeta†	CMAF‡	#Variants	Qmeta [†] CMAF [‡] #Variants Number of studies with at leat one rare variant Average number of variants in each study	Average number of variants in each study
9HXH6	5.9×10^{-11}	5.9×10 ⁻¹¹ 23537340	0.0215	32	27	12
SCN5A	1.1×10^{-7}	16604843	0.0289	35	27	13
GORASPI	1.3×10^{-5}	14361252	0.0308	16	27	9
NEBL	1.9×10^{-5}	11787699	0.0309	36	27	11
TRIML2	1.2×10^{-4}	10173978	0.0223	23	27	10
SLC22A11	1.5×10^{-4}	6539656	0.0136	11	27	6
MTRFI	2.8×10^{-4}	9073098	0.0235	10	26	3
CD36	3.5×10^{-4}	8001777	0.0156	28	27	6
CAPRIN2	3.7×10^{-4}	6886375	0.0169	15	27	7
PIK3R6	6.0×10^{-4}	9763336	0.0316	23	26	8

une gene regions

⁷Qmeta: The SKAT Q-statistic, defined as $\sum_{j=1}^{n} w_j S_j$; where w_j is the weight, and S_j is the squared score.

 ${}^{\sharp}$ CMAF: Cumulative minor allele frequency; SKAT: Sequence Kernel Association Test

The significance level for gene-based tests after Bonferroni correction was R-0.05/5759=8.7×10⁻⁶; the two genes that reached this significant cutoff are highlighted in bold font.